shouldiuse.io

Categories

VERDICT

Should I use Solidus — Life Sciences Deal Intelligence & Benchmarks?

Instant deal benchmarks, rNPV analysis, and Monte Carlo simulation for biopharma licensing, M&A, and pharma partnerships. 2,300+ verified transactions across 12 therapeutic areas and 23+ modalities. Upfront payments, milestones, royalty rates, partner matching, and AI deal memos — powered by SEC EDGAR, FTC pre-merger filings, and ClinicalTrials.gov data. Free to start. - calculator.ambrosiaventures.co

Depends. Try the free tier if you run biopharma BD or licensing and need quick deal comparables; pay the $2,500 Concierge only after a demo proves the data depth. Confidence is low — no independent reviews exist, so big pharma should benchmark it against Cortellis or Evaluate first.

Confidence

Low. Based on 3 usable public sources (product site, security page, one Reddit category thread). Most search results concerned unrelated companies named 'Solidus' — Solidus Labs (crypto compliance), Solidus ecommerce (nebulab), Solidus AI Tech, and Solidus Bio. No independent reviews of this product were found.

Ratings

  • Value for money
  • Ease of useNo user feedback found.
  • Feature depth
  • Support qualityNo evidence.
  • Security posture

Pricing

$0

Free

ModelNot disclosed
Monthly feesNot disclosed
HardwareNot disclosed
Free tierYes
Pro / ReportNot published
Concierge$2,500 one-time

Best for

  • Biopharma BD and licensing teams
  • Early-stage biotechs pricing partnerships
  • Life sciences M&A analysts
  • Teams needing fast deal comparables

Not for

  • Big pharma BD teams needing deep, audited deal data
  • Anyone outside biopharma licensing, M&A, or partnerships
  • Buyers who require independent reviews before paying
  • Solo researchers — free calculators or spreadsheets suffice

Gotchas - check before you buy

medium

Pro and Report tier prices undisclosed; only Concierge $2,500 is public.

medium

Free-tier limits (calculations, saved reports) not disclosed anywhere.

medium

Vendor's own deal counts disagree — verify database size in a demo.

low

Security is self-reported; vendors (Vercel, Supabase) are SOC 2, product untested.

Pros and cons

Pros

  • Free tier exposes 1,400+ verified deals with ~30-second results
  • rNPV, Monte Carlo, and AI deal memos in one tool
  • Covers 12 therapeutic areas and 23+ modalities
  • Data pulls from SEC EDGAR, FTC filings,
  • Granular published security controls: RLS, PKCE, encryption, rate limits

Cons

  • Deal-count claims conflict: 1,400+ vs 2,300+ across pages
  • Zero named customers or case studies on the site
  • Pro/Report tier pricing not published
  • Security posture self-reported; no third-party audit shown
  • Name collides with unrelated Solidus products, muddying research

Sources & method

Analyzed 10/01/2026 - 3 sources - No known vulnerabilities found in the sources reviewed. Self-reported posture: TLS 1.2+, AES-256 at rest, RLS, PKCE auth, Stripe PCI DSS Level 1; no third-party audit of the product itself.

official x1review x1security x1

Key stats

  • Value for money: 4/5

    Rating

  • $0

    Starting price

  • 3

    Sources

  • Analyzed

  • Value for money: 4/5. Free tier; $2,500 one-time undercuts enterprise suites.
  • Ease of use. No user feedback found.
  • Feature depth: 4/5. rNPV, Monte Carlo, 1,400+ deals, AI memos.
  • Support quality. No evidence.
  • Security posture: 4/5. Strong documented controls, but self-reported only.
  • $0 Starting price Free tier with 1,400+ deal benchmarks
  • Yes Free tier Vendor claims results in ~30 seconds
  • 1,400–2,300+ Deal database Counts conflict between homepage and tagline
  • 12 TAs, 23+ modalities Coverage Per vendor marketing

Pricing

Free

$0

  • 1,400+ verified deal benchmarks
  • Results in ~30 seconds
  • Usage limits undisclosed

Pro / Report

Not published

  • Tiers exist per security docs
  • Prices and features unpublished

Concierge

$2,500 one-time

  • Intelligence Brief
  • Maps full landscape, all modalities

Security

No known vulnerabilities found in the sources reviewed.

Self-reported posture: TLS 1.2+, AES-256 at rest, RLS, PKCE auth, Stripe PCI DSS Level 1; no third-party audit of the product itself.

What users say

No independent user reviews of Solidus surfaced in the sources reviewed; Reddit discussion covers rival pharma intelligence platforms.

Alternatives

Compare Solidus — Life Sciences Deal Intelligence & Benchmarks with each alternative.

  • Excel + SEC EDGAR (DIY)

    Free DIY valuation modeling; slower but fine for occasional deals.

Full analysis

Based on 3 usable public sources (product site, security page, one Reddit category thread). Most search results concerned unrelated companies named 'Solidus' — Solidus Labs (crypto compliance), Solidus ecommerce (nebulab), Solidus AI Tech, and Solidus Bio. No independent reviews of this product were found.

Free tier makes it a cheap test for biopharma deal benchmarking; no independent reviews — vet before paying $2,500.

Methodology

Based on 3 usable public sources (product site, security page, one Reddit category thread). Most search results concerned unrelated companies named 'Solidus' — Solidus Labs (crypto compliance), Solidus ecommerce (nebulab), Solidus AI Tech, and Solidus Bio. No independent reviews of this product were found.

Sources

  1. Solidus — Life Sciences Deal Intelligence & Benchmarkscalculator.ambrosiaventures.co
    official
  2. Product security page — Ambrosia Venturescalculator.ambrosiaventures.co
    security
  3. Anyone use a Pharma Intelligence Platform? : r/biotechreddit.com
    review

Rate this review

Anonymous. You can change your vote.

Loading votes…

Comments

One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.

Save a name to write a comment.

0 / 200 words

No comments yet.